“Acetic Acid Chromoendoscopy in Barrett’s Esophagus Surveillance

Overview

Neoplasia in Barrett's esophagus could be missed during routine random biopsies. We propose a study using chromoendoscopy with Acetic Acid to increase the yield of biopsies in detecting neoplasia.

Full Title of Study: “”Acetic Acid Chromoendoscopy in Barrett’s Esophagus Surveillance is Superior to the Standardized Random Biopsy Protocol in Detecting Neoplasia: A Prospective Randomized Study””

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: July 30, 2018

Detailed Description

Neoplasia in Barrett's esophagus is often focal and can be missed by nontargeted biopsies alone. In recent years, various advanced endoscopic techniques have been utilized, but with varying success rates. Narrow-band imaging, trimodal imaging, spectral imaging and i-scan are technologies that are manufacturer dependent with limited varying success rates and have financial implications. At our institution, narrow band imaging is routinely utilized as a diagnostic tool for detecting Barrett's esophagus. Acetic acid is a commonly available dye that has been used in the detection of neoplasia in Barrett's esophagus. This study is aimed to prove the effectiveness of acetic acid chromoendoscopy in our Barrett's esophagus surveillance population. The goal is to compare the neoplasia yield of acetic acid chromoendoscopy with that of standardized random biopsy protocol. The sensitivity and specificity for neoplasia detection by these two methods will also be analyzed. Investigators plan to conduct this prospective randomized study for a period of one and a half years (beginning August 1, 2015, ending February 29, 2016). Based on data from 2014, we anticipate to enroll approximately 185 patients. All gastroenterologists (with privileges at Doctors Hospital at Renaissance) will participate in this study. Patients will be randomized to either acetic acid chromoendoscopy or current standard of care (standardized random biopsy protocol utilizing narrow band imaging). Random biopsies from both protocols and targeted biopsies (if identified) will be obtained and submitted to pathology department. These will be reviewed independently by two pathologists. Any discordant results will be reviewed by an outside expert pathologist. Statistical data analysis will be performed utilizing Datadesk XL software.

Interventions

  • Drug: Chromoendoscopy using Acetic Acid 2.5%
    • Spraying esophageal mucosa during random biopsies for Barrett’s esophagus
  • Other: Standard random esophageal biopsies
    • Random esophageal biopsies performed as per protocol

Arms, Groups and Cohorts

  • Experimental: Chromoendoscopy using Acetic Acid 2.5%
    • Patient will have endoscopic examination of esophagus. Esophageal mucosa sprayed with 5cc solution of Acetic Acid 2.5% one time only. Esophageal mucosa examined again. Biopsies are obtained. Abnormal areas identified by Acetic Acid 2.5% will be submitted on separate containers for pathology review. If no abnormalities seen, random biopsies taken as per standard recommendations for Barrett’s esophagus. Samples submitted for pathology review.
  • Active Comparator: Standard random esophageal biopsies
    • Patient will have endoscopic examination of the esophagus. Esophageal mucosa will not be sprayed with Acetic Acid 2.5%. Random biopsies taken as per standard recommendations for Barrett’s esophagus. Samples submitted for pathology review.

Clinical Trial Outcome Measures

Primary Measures

  • Total Number of Subjects With Neoplasia When Using Acetic Acid Chromoendoscopy Versus Standardized Random Biopsies.
    • Time Frame: 142 seconds
    • Spray of Acetic Acid into the esophageal mucosa during routine esophageal biopsies for Barrett’s esophagus surveillance increases the yield of neoplasia.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients 18 years and older – Previous diagnosis of Barrett's esophagus, confirmed by pathology. Exclusion Criteria:

  • Patients diagnosed with any level of dysplasia on previous esophageal biopsies. – Patients who had esophageal therapy with Halo radiofrequency ablation in the past, or esophagectomy. – History of allergy to Acetic Acid – History of esophageal dysplasia or cancer – Esophageal ulcerations – Esophageal Candida – Esophageal Varices – Patients with active esophagitis – Patients who cannot provide a valid consent – Patients who are currently pregnant

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • DHR Health Institute for Research and Development
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ingrid Chacon, Gastroenterology Specialist – DHR Health Institute for Research and Development
  • Overall Official(s)
    • Ingrid M Chacon, MD, Principal Investigator, Doctor’s Hospital at Renaissance

References

Longcroft-Wheaton G, Duku M, Mead R, Poller D, Bhandari P. Acetic acid spray is an effective tool for the endoscopic detection of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2010 Oct;8(10):843-7. doi: 10.1016/j.cgh.2010.06.016. Epub 2010 Jun 30.

Tholoor S, Bhattacharyya R, Tsagkournis O, Longcroft-Wheaton G, Bhandari P. Acetic acid chromoendoscopy in Barrett's esophagus surveillance is superior to the standardized random biopsy protocol: results from a large cohort study (with video). Gastrointest Endosc. 2014 Sep;80(3):417-24. doi: 10.1016/j.gie.2014.01.041. Epub 2014 Apr 6.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.